Golbakhsh Mohammad Reza, Boddouhi Bahram, Hatami Negin, Goudarzi Peyman Karimi, Shakeri Mohammadreza, Yahaghi Emad, Taheriazam Afshin
Department of Orthopedics, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Department of Orthopedic Surgery, Rasoul-e-Akram Hospital, Iran University of Medical Science, Tehran, Iran.
Arch Med Sci. 2017 Oct;13(6):1352-1356. doi: 10.5114/aoms.2016.60091. Epub 2016 May 20.
The aim of this study was to investigate the expression levels of microRNA-182 and microRNA-183 and their association with clinicopathological features in patients with osteosarcoma.
Total RNA was purified from samples and noncancerous bone tissues and then quantitative real-time polymerase chain reaction was applied to evaluate the expression levels of microRNAs, and their relationship with clinicopathological features and survival in osteosarcoma patients.
Our findings showed that expression of MiR-182 was clearly lower in osteosarcoma bone tissue (mean ± SD: 2.84 ±.07) compared with noncancerous bone tissues (6.23 ±1.72, = 0.004). On the other hand, lower expression of MiR-183 was seen in osteosarcoma bone tissue (1.43 ±0.59) when compared with normal tissues (4.36 ±2.47, = 0.036). Decreased expression of MiR-182 was clearly correlated with advanced clinical stage ( = 0.001), metastasis or recurrence ( = 0.024), and large tumor size ( = 0.032). Decreased expression of MiR-183 was associated with advanced TNM stage ( = 0.004), and metastasis or recurrence ( = 0.002). A multivariate Cox proportional hazards model revealed that low expression of MiR-182 and MiR-183 ( = 0.02; = 0.016), TNM stage ( = 0.04), and metastasis or recurrence ( = 0.03) were significantly associated with poor survival as independent prognostic factors.
These findings suggest that MiR-182 and MiR-183 may be associated with progression and metastasis of osteosarcoma.
本研究旨在调查骨肉瘤患者中微小RNA - 182和微小RNA - 183的表达水平及其与临床病理特征的关系。
从样本和非癌性骨组织中纯化总RNA，然后应用定量实时聚合酶链反应评估微小RNA的表达水平，以及它们与骨肉瘤患者临床病理特征和生存的关系。
我们的研究结果表明，与非癌性骨组织（6.23±1.72）相比，骨肉瘤骨组织中MiR - 182的表达明显较低（平均值±标准差：2.84±0.07，P = 0.004）。另一方面，与正常组织（4.36±2.47）相比，骨肉瘤骨组织中MiR - 183的表达较低（1.43±0.59，P = 0.036）。MiR - 182表达降低与临床晚期（P = 0.001）、转移或复发（P = 0.024）以及肿瘤体积大（P = 0.032）明显相关。MiR - 183表达降低与TNM晚期（P = 0.004）以及转移或复发（P = 0.002）相关。多变量Cox比例风险模型显示，MiR - 182和MiR - 183低表达（P = 0.02；P = 0.016）、TNM分期（P = 0.04）以及转移或复发（P = 0.03）作为独立预后因素与不良生存显著相关。
这些发现表明MiR - 182和MiR - 183可能与骨肉瘤的进展和转移有关。
